Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Yuru, Lu, Weiqing, Chen, Daiyu, Tu, Huilin, Guo, Zhenling, Zhou, Xuan, Li, Meifang, Tu, Sanfang, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254656/
https://www.ncbi.nlm.nih.gov/pubmed/32514351
http://dx.doi.org/10.1186/s40364-020-00197-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254656/
https://www.ncbi.nlm.nih.gov/pubmed/32514351
http://dx.doi.org/10.1186/s40364-020-00197-1

Ejemplares similares